PErsonalized TReatment for Endometrial Carcinoma

The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas.Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup.Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.

Inclusion Criteria:Age 18 to 100 yearsWHO performance status 0 to 2Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinomaExclusion Criteria:Age <18 years or >100 yearsWHO performance status >2Uterine sarcomaA history of malignancy within 5 yearsPrevious pelvic radiotherapyAn interval of >30 days between surgery and start of chemotherapy or >8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)